1413431-25-0

Basic information

• Product Name: 2,4-di(tert-butyl-d₉)-3,5,6-d₃-phenol
• Synonyms: 2,4-di(tert-butyl-d₉)-3,5,6-d₃-phenol
• CAS NO: 1413431-25-0
• Molecular Weight: 227.161
• Mol File: 1413431-25-0.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 2,4-di(tert-butyl-d₉)-3,5,6-d₃-phenol(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-di(tert-butyl-d₉)-3,5,6-d₃-phenol(1413431-25-0)
• EPA Substance Registry System: 2,4-di(tert-butyl-d₉)-3,5,6-d₃-phenol(1413431-25-0)

Safety Data

• Hazardous Substances Data: 1413431-25-0(Hazardous Substances Data)

Upstream product

• 918-20-7 tert-butyl chloride-d9 
• 13127-88-3 phenol-d6 

Downstream Products

• 1413431-26-1 2,4-di(tert-butyl-d₉)-3,5,6-d₃-phenylmethyl carbonate 
• 1413431-27-2 2,4-di(tert-butyl-d₉)-3,6-d₂-5-nitrophenol 
• 1413431-28-3 5-amino-2,4-di(tert-butyl-d₉)-3,6-d₂-phenol 
• 1413430-93-9 N-(2,4-di(tert-butyl-d₉)-3,6-d₂-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide 

Relevant articles and documents

DEUTERATED CFTR POTENTIATORS

The present invention relates to a compound of chemical formula I and pharmaceutically acceptable salts thereof. The present invention also provides a composition comprising the compound in the present invention and the use of the composition in a method for treatment of diseases and conditions which are beneficially treated by administering a CFTR potentiator.

DEUTERATED CFTR POTENTIATOR

PROBLEM TO BE SOLVED: To provide compositions comprising novel ivacaftor derivatives and pharmaceutically acceptable salts thereof for treating diseases and conditions that are beneficially treated by administering a CFTR (cystic fibrosis transmembrane co

DEUTERATED CFTR ENHANCEMENT MATERIAL

PROBLEM TO BE SOLVED: To provide a compound to treat cystic fibrosis. SOLUTION: The present invention provides a pharmaceutical composition comprising a compound represented by formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier thereof [X1-X7 independently represent H or D; Y1-Y6 independently represent CH3 or CD3; if all of Y1-Y6 are CH3, at least one of X1-X7 is D]. SELECTED DRAWING: None COPYRIGHT: (C)2017,JPOandINPIT